6 completed, 2 withdrawn, 1 unknown. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Blade Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) Cudetaxestat (BLD-0409), Control: Matching Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | Blade Therapeutics | 200 | 2022-05-31 | 2022-05-18 |
| Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet - Drug Drug Interaction | Phase 1 | Completed | Blade Therapeutics | 86 | 2021-10-15 | 2022-04-15 |
| Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations BLD-0409 - Relative Bioavailability | Phase 1 | Completed | Blade Therapeutics | 34 | 2021-05-16 | 2021-11-10 |
| Drug-Drug Interaction (DDI) Study in Healthy Volunteers Geneva Cocktail, BLD-0409 - Drug Drug Interaction | Phase 1 | Completed | Blade Therapeutics | 16 | 2021-05-03 | 2022-05-17 |
| Healthy Volunteer Study Comparing Tablet and Capsule Formulations BLD-2660 - Fibrosis | Phase 1 | Withdrawn | Blade Therapeutics | 2021-02-01 | 2020-10-30 | |
| Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects BLD-2660 - Sars-CoV-2, Covid19 | Phase 2 | Completed | Blade Therapeutics | 120 | 2020-05-04 | 2022-04-06 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects BLD-0409, Control: Placebo - Chronic Liver Disease, NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Blade Therapeutics | 80 | 2020-01-10 | 2021-06-04 |
| Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF BLD-2660, Control: Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Withdrawn | Blade Therapeutics | 2019-12-15 | 2021-03-04 | |
| First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis BLD-2660 - Fibrosis | Phase 1 | Completed | Blade Therapeutics | 88 | 2018-07-11 | 2020-03-19 |
Fibrosis (2) · Idiopathic Pulmonary Fibrosis (2) · COVID-19 (1) · Non-alcoholic Fatty Liver Disease (1) · Pulmonary Fibrosis (1)
Tablets (1) · nintedanib (1) · pirfenidone (1)
Australia (5) · United States (2) · Brazil (1) · United Kingdom (1)
Ben Snyder, MD (1) · Charlotte Lemech, MD (1) · Christopher Argent, MD (1) · Kimberly S Cruz, MD (1) · Kristi McLendon, MD (1)